Awakn Life Sciences

Awakn’s aminoindane NCE program, developed in collaboration with Graft Polymer (UK) Plc, is designed to address significant unmet medical needs, including PTSD, which affects approximately 13 million adults in the U.S. and 20 million individuals across the U.S., UK, and Europe. https://bit.ly/4g9KEnB

Graft Polymer (UK) Plc chairman Dennis Purcell sat with Proactive's Stephen Gunnion to discuss the Company's proposed strategic acquisition of Awakn Life Sciences to help build an integrated #mentalhealth focused entity. Watch the full interview, here:https://bit.ly/400E9hc

Professor David Nutt, Chief Research Officer of Awakn, comments on the Company's latest milestone in the co-led aminoindane NCE program and highlights its potential for treating #PTSD and other trauma-related conditions. https://bit.ly/4g9KEnB

Awakn Life Sciences Enters Into Binding Letter of Intent for Acquisition of Awakn by Graft Polymer (UK) PLC. https://bit.ly/49MGlME

Dr. Madeleine King, from the School of Life Sciences at the University of Nottingham, and study lead has recently shed light on the promising findings from the co-led aminoindane new chemical entity pre-clinical program. Read more: https://bit.ly/4g9KEnB #addiction #mentalhealth #PTSD

Based on the recent promising results, Awakn will expand its aminoindane program to synthesize a further range of aminoindane compounds in collaboration with Concept Life Sciences. These compounds will be screened against serotonin, dopamine, and norepinephrine release. Additional preclinical behavioral studies with the University of Nottingham are also planned to further explore and validate the therapeutic potential of this class of compounds. Learn more: https://bit.ly/4g9KEnB

Awakn announced initial results from a preclinical study of its co-lead aminoindane series (AW21003) conducted by the University of Nottingham. This program focuses on new therapeutic options for trauma-related #mentalhealth disorders, particularly Post-Traumatic Stress Disorder (#PTSD). For additional details, visit: https://bit.ly/4g9KEnB

#AUD remains a significant global concern, with 40mil people suffering in the US, UK, and key European markets alone. Awakn's therapeutics offer a novel approach to treating #AUD, with the potential to be more effective than current treatments. https://bit.ly/3A0ipTQ

Awakn's goal is to provide breakthrough therapeutics to #addiction sufferers in desperate need and our strategy is focused on commercialising our R&D pipeline across multiple channels. Please visit our website for more information: https://bit.ly/3whvhSX

Did you know #AlcoholUseDisorder affects 285 Million people globally, yet only 10% of AUD sufferers in the US, UK, and big 4 European markets seek treatment, and up to 75% of those people relapse within 12 months? Find how Awakn is developing therapeutics to help address #addictions such as #AUD, here: https://bit.ly/3whvhSX